Doctor Mason Freeman

CinCor Pharma, Boston (United States of America)

Membership: ESC Professional Member

Follow

Contributor content

Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

Presentation

Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107

ESC 365 is supported by

novartis

Explore sponsored resources